PHOTOCURE ASA (PHO.OL) Stock Fundamental Analysis
Europe - Euronext Oslo - OSL:PHO - NO0010000045 - Common Stock
68.4 NOK
+2.2 (+3.32%)
Overall PHO gets a fundamental rating of 4 out of 10. We evaluated PHO against 53 industry peers in the Pharmaceuticals industry. While PHO has a great health rating, there are worries on its profitability. While showing a medium growth rate, PHO is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year PHO was profitable.
PHO had a positive operating cash flow in the past year.
In the past 5 years PHO reported 4 times negative net income.
Of the past 5 years PHO 4 years had a positive operating cash flow.
1.2 Ratios
PHO has a Return On Assets of -0.78%. This is in the lower half of the industry: PHO underperforms 66.04% of its industry peers.
The Return On Equity of PHO (-1.11%) is worse than 66.04% of its industry peers.
PHO has a worse Return On Invested Capital (0.11%) than 69.81% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.78% | ||
| ROE | -1.11% | ||
| ROIC | 0.11% |
ROA(3y)-3.44%
ROA(5y)-3.42%
ROE(3y)-5.33%
ROE(5y)-5.31%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PHO has a worse Operating Margin (0.17%) than 69.81% of its industry peers.
PHO's Operating Margin has declined in the last couple of years.
With an excellent Gross Margin value of 93.40%, PHO belongs to the best of the industry, outperforming 96.23% of the companies in the same industry.
In the last couple of years the Gross Margin of PHO has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 0.17% | ||
| PM (TTM) | N/A | ||
| GM | 93.4% |
OM growth 3YN/A
OM growth 5Y-23.87%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.29%
GM growth 5Y0.46%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PHO is destroying value.
PHO has about the same amout of shares outstanding than it did 1 year ago.
PHO has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, PHO has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 6.48 indicates that PHO is not in any danger for bankruptcy at the moment.
PHO's Altman-Z score of 6.48 is amongst the best of the industry. PHO outperforms 88.68% of its industry peers.
PHO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 6.48 |
ROIC/WACC0.01
WACC8.5%
2.3 Liquidity
PHO has a Current Ratio of 4.78. This indicates that PHO is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of PHO (4.78) is better than 96.23% of its industry peers.
PHO has a Quick Ratio of 4.29. This indicates that PHO is financially healthy and has no problem in meeting its short term obligations.
PHO has a Quick ratio of 4.29. This is amongst the best in the industry. PHO outperforms 94.34% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.78 | ||
| Quick Ratio | 4.29 |
3. Growth
3.1 Past
PHO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -93.88%.
PHO shows a small growth in Revenue. In the last year, the Revenue has grown by 4.94%.
The Revenue has been growing by 13.29% on average over the past years. This is quite good.
EPS 1Y (TTM)-93.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%215.38%
Revenue 1Y (TTM)4.94%
Revenue growth 3Y13.37%
Revenue growth 5Y13.29%
Sales Q2Q%12.26%
3.2 Future
Based on estimates for the next years, PHO will show a very strong growth in Earnings Per Share. The EPS will grow by 170.05% on average per year.
The Revenue is expected to grow by 14.98% on average over the next years. This is quite good.
EPS Next Y916.42%
EPS Next 2Y173.5%
EPS Next 3Y170.05%
EPS Next 5YN/A
Revenue Next Year12.38%
Revenue Next 2Y9.18%
Revenue Next 3Y11.27%
Revenue Next 5Y14.98%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 2280.00 indicates a quite expensive valuation of PHO.
Based on the Price/Earnings ratio, PHO is valued a bit more expensive than the industry average as 67.92% of the companies are valued more cheaply.
The average S&P500 Price/Earnings ratio is at 26.38. PHO is valued rather expensively when compared to this.
With a Price/Forward Earnings ratio of 69.34, PHO can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, PHO is valued a bit more expensive than 69.81% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.83. PHO is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 2280 | ||
| Fwd PE | 69.34 |
4.2 Price Multiples
73.58% of the companies in the same industry are cheaper than PHO, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of PHO indicates a slightly more expensive valuation: PHO is more expensive than 62.26% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 53.38 | ||
| EV/EBITDA | 51.76 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as PHO's earnings are expected to grow with 170.05% in the coming years.
PEG (NY)2.49
PEG (5Y)N/A
EPS Next 2Y173.5%
EPS Next 3Y170.05%
5. Dividend
5.1 Amount
PHO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
OSL:PHO (12/19/2025, 7:00:00 PM)
68.4
+2.2 (+3.32%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners43.64%
Inst Owner ChangeN/A
Ins Owners1.95%
Ins Owner ChangeN/A
Market Cap1.86B
Revenue(TTM)525.39M
Net Income(TTM)-5.33M
Analysts82.5
Price Target81.6 (19.3%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)138.57%
Min EPS beat(2)15.13%
Max EPS beat(2)262.02%
EPS beat(4)3
Avg EPS beat(4)30.25%
Min EPS beat(4)-203.96%
Max EPS beat(4)262.02%
EPS beat(8)5
Avg EPS beat(8)48.5%
EPS beat(12)7
Avg EPS beat(12)20.94%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.58%
Min Revenue beat(2)-5.24%
Max Revenue beat(2)2.07%
Revenue beat(4)2
Avg Revenue beat(4)-0.99%
Min Revenue beat(4)-5.24%
Max Revenue beat(4)2.07%
Revenue beat(8)3
Avg Revenue beat(8)-3.45%
Revenue beat(12)6
Avg Revenue beat(12)-2.68%
Revenue beat(16)7
Avg Revenue beat(16)-4.3%
PT rev (1m)0.63%
PT rev (3m)0.63%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)111.89%
EPS NY rev (3m)155.26%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.58%
Revenue NY rev (1m)0.35%
Revenue NY rev (3m)2.48%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 2280 | ||
| Fwd PE | 69.34 | ||
| P/S | 3.55 | ||
| P/FCF | 53.38 | ||
| P/OCF | 40.27 | ||
| P/B | 3.87 | ||
| P/tB | 7.47 | ||
| EV/EBITDA | 51.76 |
EPS(TTM)0.03
EY0.04%
EPS(NY)0.99
Fwd EY1.44%
FCF(TTM)1.28
FCFY1.87%
OCF(TTM)1.7
OCFY2.48%
SpS19.28
BVpS17.69
TBVpS9.15
PEG (NY)2.49
PEG (5Y)N/A
Graham Number3.46
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.78% | ||
| ROE | -1.11% | ||
| ROCE | 0.14% | ||
| ROIC | 0.11% | ||
| ROICexc | 0.18% | ||
| ROICexgc | 0.49% | ||
| OM | 0.17% | ||
| PM (TTM) | N/A | ||
| GM | 93.4% | ||
| FCFM | 6.65% |
ROA(3y)-3.44%
ROA(5y)-3.42%
ROE(3y)-5.33%
ROE(5y)-5.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-14.8%
ROICexc growth 3YN/A
ROICexc growth 5Y-32.88%
OM growth 3YN/A
OM growth 5Y-23.87%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.29%
GM growth 5Y0.46%
F-Score4
Asset Turnover0.76
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 38.76% | ||
| Cap/Sales | 2.16% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 153.21% | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.78 | ||
| Quick Ratio | 4.29 | ||
| Altman-Z | 6.48 |
F-Score4
WACC8.5%
ROIC/WACC0.01
Cap/Depr(3y)33%
Cap/Depr(5y)196.94%
Cap/Sales(3y)1.85%
Cap/Sales(5y)14.41%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-93.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%215.38%
EPS Next Y916.42%
EPS Next 2Y173.5%
EPS Next 3Y170.05%
EPS Next 5YN/A
Revenue 1Y (TTM)4.94%
Revenue growth 3Y13.37%
Revenue growth 5Y13.29%
Sales Q2Q%12.26%
Revenue Next Year12.38%
Revenue Next 2Y9.18%
Revenue Next 3Y11.27%
Revenue Next 5Y14.98%
EBIT growth 1Y-97.81%
EBIT growth 3YN/A
EBIT growth 5Y-13.75%
EBIT Next Year133.71%
EBIT Next 3Y72.02%
EBIT Next 5YN/A
FCF growth 1Y-3.32%
FCF growth 3Y47.91%
FCF growth 5Y27.04%
OCF growth 1Y9.51%
OCF growth 3Y47.56%
OCF growth 5Y30.02%
PHOTOCURE ASA / PHO.OL FAQ
What is the fundamental rating for PHO stock?
ChartMill assigns a fundamental rating of 4 / 10 to PHO.OL.
Can you provide the valuation status for PHOTOCURE ASA?
ChartMill assigns a valuation rating of 1 / 10 to PHOTOCURE ASA (PHO.OL). This can be considered as Overvalued.
Can you provide the profitability details for PHOTOCURE ASA?
PHOTOCURE ASA (PHO.OL) has a profitability rating of 2 / 10.
What is the valuation of PHOTOCURE ASA based on its PE and PB ratios?
The Price/Earnings (PE) ratio for PHOTOCURE ASA (PHO.OL) is 2280 and the Price/Book (PB) ratio is 3.87.
How financially healthy is PHOTOCURE ASA?
The financial health rating of PHOTOCURE ASA (PHO.OL) is 9 / 10.